Role and treatment of mitochondrial dna-related mitochondrial dysfunction in sporadic neurodegenerative diseases

Current Pharmaceutical Design

Volumn 17, Issue 31, 2011, Pages 3356-3373

  Swerdlow, Russell H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cybrids; Endophenotype; Mitochondria; Mitochondrial DNA; Mitochondrial medicine; Neurodegenerative disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOACETIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; DICHLOROACETIC ACID; DIMEBON; DNA DIRECTED DNA POLYMERASE GAMMA; IDEBENONE; MENADIONE; METHYLENE BLUE; MINOCYCLINE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MONOAMINE OXIDASE B INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; PIOGLITAZONE; PROTEIN BCL 2; PYRUVATE DEHYDROGENASE KINASE; RAPAMYCIN; RIBOFLAVIN; RIBOSOME RNA; ROSIGLITAZONE; UBIQUINONE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATAXIA; AUTOPHAGY; BLOOD BRAIN BARRIER; BLOOD LEVEL; CELL FUNCTION; CELL SWELLING; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FRIEDREICH ATAXIA; GENE MUTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VITRO STUDY; KETOGENIC DIET; LACTIC ACIDOSIS; LOW DRUG DOSE; METHEMOGLOBINEMIA; MIGRAINE; MITOCHONDRIAL ENCEPHALOPATHY; MNGIE SYNDROME; MYOCLONUS EPILEPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY CHAIN; RETINITIS PIGMENTOSA; RNA TRANSLATION; SEIZURE;

DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES;

EID: 80055078025     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798072535     Document Type: Article

References (316)

1. Swerdlow RH. The neurodegenerative mitochondriopathies. J Alzheimers Dis 2009; 17: 737-51.
2. Swerdlow RH. Treating neurodegeneration by modifying mitochondria: potential solutions to a complex problem. Antioxid Redox Signal 2007; 9: 1591-603.
3. Swerdlow RH. Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence. Antioxid Redox Signal 2011: Epub ahead of print.
4. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 2010; 20 Suppl 2: S265-279.
5. Swerdlow RH, Parks JK, Pattee G, Parker WD, Jr. Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 185-190.
6. Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992; 59: 776-779.
7. Parker WD, Jr., Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-723.
8. Parker WD, Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990; 40: 1302-1303.
9. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1: 1269.
10. Swerdlow RH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol Aging 2007; 28: 1465-1480.
11. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996; 14: 317-335.
12. Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet 2003; 63: 83-101.
13. Mosconi L, Berti V, Swerdlow RH, Pupi A, Duara R, de Leon M. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics 2010; 4: 170-193.
14. Swerdlow RH, Parker WD, Currie LJ, et al. Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat Disord 2001; 7: 129-133.
15. Swerdlow RH, Parks JK, Davis JN, et al. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 1998; 44: 873-881.
16. Swerdlow RH. Mitochondrial DNA--related mitochondrial dysfunction in neurodegenerative diseases. Arch Pathol Lab Med 2002; 126: 271-280.
17. Luft R. The development of mitochondrial medicine. Proc Natl Acad Sci USA 1994; 91: 8731-8738.
18. Swerdlow RH. Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals 2009; 2: 150-167.
19. Haller RG, Vissing J. Drilling for energy in mitochondrial disease. Arch Neurol 2009; 66: 931-932.
20. Armstrong JS. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007; 151: 1154-1165.
21. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290: 457-465.
22. Clayton DA. Transcription and replication of mitochondrial DNA. Hum Reprod 2000; 15 Suppl 2: 11-17.
23. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990; 348: 651-653.
24. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61: 931-937.
25. Rojo A, Campos Y, Sanchez JM, et al. NARP-MILS syndrome caused by 8993 T>G mitochondrial DNA mutation: a clinical, genetic and neuropathological study. Acta Neuropathol 2006; 111: 610-616.
26. Newman NJ. Leber's hereditary optic neuropathy. New genetic considerations. Arch Neurol 1993; 50: 540-548.
27. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242: 1427-1430.
28. Lara MC, Valentino ML, Torres-Torronteras J, Hirano M, Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci Rep 2007; 27: 151-163.
29. Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006; 59: 859-862.
30. Hudson G, Schaefer AM, Taylor RW, et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007; 64: 553-557.
31. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004; 364: 875-882.
32. Luoma PT, Eerola J, Ahola S, et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 2007; 69: 1152-1159.
33. Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309: 481-484.
34. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429: 417-423.
35. Parker WD. Sporadic neurologic disease and the electron transport chain: a hypothesis. In: Pascuzzi RM, editor. Proceedings of the 1989 Scientfic Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease Bloomington, Indiana: Indiana University Printing Services; 1990.
36. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992; 256: 628-32.
37. Parker WD, Jr., Swerdlow RH. Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet 1998; 62: 758-62.
38. Swerdlow RH, Kish SJ. Mitochondria in Alzheimer's disease. Int Rev Neurobiol 2002; 53: 341-85.
39. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
40. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine. Life Sci 1985; 36: 2503-8.
41. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-6.
42. Swerdlow RH. Mitochondria and Parkinson's Disease. In: Chesselet M-F, editor. Molecular Mechanisms of Neurodegenerative Diseases. Totowa, New Jersey: Humana Press; 2000.
43. Bennett MC, Diamond DM, Stryker SL, Parks JK, Parker WD, Jr. Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. J Geriatr Psychiatry Neurol 1992; 5: 93-101.
44. Lu J, Wang K, Rodova M, et al. Polymorphic variation in cytochrome oxidase subunit genes. J Alzheimers Dis 2010; 21: 141-54.
45. Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet 2002; 11: 133-45.
46. Parker WD, Jr., Parks JK. Mitochondrial ND5 mutations in idiopathic Parkinson's disease. Biochem Biophys Res Commun 2005; 326: 667-9.
47. Simon DK, Lin MT, Zheng L, et al. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging 2004; 25: 71-81.
48. Smigrodzki R, Parks J, Parker WD. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol Aging 2004; 25: 1273-81.
49. Cantuti-Castelvetri I, Lin MT, Zheng K, et al. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging 2005; 26: 1343-55.
50. Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 2007; 85: 3416-28.
51. Bunn CL, Wallace DC, Eisenstadt JM. Cytoplasmic inheritance of chloramphenicol resistance in mouse tissue culture cells. Proc Natl Acad Sci USA 1974; 71: 1681-5.
52. Wallace DC, Bunn CL, Eisenstadt JM. Cytoplasmic transfer of chloramphenicol resistance in human tissue culture cells. J Cell Biol 1975; 67: 174-88.
53. Chomyn A, Martinuzzi A, Yoneda M, et al. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci USA 1992; 89: 4221-5.
54. King MP, Koga Y, Davidson M, Schon EA. Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Mol Cell Biol 1992; 12: 480-90.
55. Chomyn A, Lai ST, Shakeley R, Bresolin N, Scarlato G, Attardi G. Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals--and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers. Am J Hum Genet 1994; 54: 966-74.
56. Masucci JP, Davidson M, Koga Y, Schon EA, King MP. In vitro analysis of mutations causing myoclonus epilepsy with ragged-red fibers in the mitochondrial tRNA(Lys)gene: two genotypes produce similar phenotypes. Mol Cell Biol 1995; 15: 2872-81.
57. Hofhaus G, Johns DR, Hurko O, Attardi G, Chomyn A. Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy. J Biol Chem 1996; 271: 13155-61.
58. Vergani L, Martinuzzi A, Carelli V, et al. MtDNA mutations associated with Leber's hereditary optic neuropathy: studies on cytoplasmic hybrid (cybrid) cells. Biochem Biophys Res Commun 1995; 210: 880-8.
59. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246: 500-3.
60. Miller SW, Trimmer PA, Parker WD, Jr., Davis RE. Creation and characterization of mitochondrial DNA-depleted cell lines with neuronal-like properties. J Neurochem 1996; 67: 1897-907.
61. Binder DR, Dunn WH, Jr., Swerdlow RH. Molecular characterization of mtDNA depleted and repleted NT2 cell lines. Mitochondrion 2005; 5: 255-65.
62. Ephrussi B, Hottinger H, Chimenes A. Action de l'acriflavine sur les levures, I: la mutation petite clonie. Ann Inst Pasteur 1949; 76: 531.
63. Morais R, Desjardins P, Turmel C, Zinkewich-Peotti K. Development and characterization of continuous avian cell lines depleted of mitochondrial DNA. In Vitro Cell Dev Biol 1988; 24: 649-58.
64. Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 2006; 22: 79-99.
65. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009; 18: R169-76.
66. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 2004; 89: 1417-26.
67. Sheehan JP, Swerdlow RH, Miller SW, et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 1997; 17: 4612-22.
68. Swerdlow RH, Parks JK, Cassarino DS, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997; 49: 918-25.
69. Esteves AR, Domingues AF, Ferreira IL, et al. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron- like nuclear background. Mitochondrion 2008; 8: 219-28.
70. Gu M, Cooper JM, Taanman JW, Schapira AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998; 44: 177-86.
71. Shults CW, Miller SW. Reduced complex I activity in parkinsonian cybrids. Movement Disorders 1998; 13(suppl. 2): 217.
72. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40: 663-71.
73. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998; 153: 135-42.
74. Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 2000; 123 (Pt 7): 1339-48.
75. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998; 156: 65-72.
76. Swerdlow RH, Golbe LI, Parks JK, et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 2000; 75: 1681-4.
77. Cassarino DS, Fall CP, Swerdlow RH, et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1997; 1362: 77-86.
78. Khan SM, Cassarino DS, Abramova NN, et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 2000; 48: 148-55.
79. Domingues AF, Arduino DM, Esteves AR, Swerdlow RH, Oliveira CR, Cardoso SM. Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. Free Radic Biol Med 2008; 45: 820-5.
80. Esteves AR, Arduino DM, Swerdlow RH, Oliveira CR, Cardoso SM. Oxidative Stress involvement in alpha-synuclein oligomerization in Parkinsons disease cybrids. Antioxid Redox Signal 2008.
81. Albers DS, Swerdlow RH, Manfredi G, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 2001; 168: 196-8.
82. Trimmer PA, Borland MK, Keeney PM, Bennett JP, Jr., Parker WD, Jr. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 2004; 88: 800-12.
83. Trimmer PA, Swerdlow RH, Parks JK, et al. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 2000; 162: 37-50.
84. Swerdlow RH, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 2009; 218: 308-15.
85. D'Aurelio M, Vives-Bauza C, Davidson MM, Manfredi G. Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells. Hum Mol Genet 2010; 19: 374-86.
86. Dunbar DR, Moonie PA, Zeviani M, Holt IJ. Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids. Hum Mol Genet 1996; 5: 123-29.
87. Bornstein B, Mas JA, Patrono C, et al. Comparative analysis of the pathogenic mechanisms associated with the G8363A and A8296G mutations in the mitochondrial tRNA(Lys) gene. Biochem J 2005; 387: 773-8.
88. Swerdlow RH, Weaver B, Grawey A, Wenger C, Freed E, Worrall BB. Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease. J Neurol Sci 2006; 247: 224-30.
89. Corral-Debrinski M, Horton T, Lott MT, et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994; 23: 471-6.
90. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 2004; 101: 10726-31.
91. Coskun PE, Wyrembak J, Derbereva O, et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis 2010; 20 Suppl 2: S293-310.
92. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-7.
93. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006; 38: 518-20.
94. Mancuso M, Conforti FL, Rocchi A, et al. Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis? Neurosci Lett 2004; 371: 158-62.
95. van der Walt JM, Dementieva YA, Martin ER, et al. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett 2004; 365: 28-32.
96. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003; 72: 804-11.
97. Autere J, Moilanen JS, Finnila S, et al. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet 2004; 115: 29-35.
98. Ghezzi D, Marelli C, Achilli A, et al. Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet 2005; 13: 748-52.
99. Pyle A, Foltynie T, Tiangyou W, et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 2005; 57: 564-7.
100. Katzman R. Alzheimer's disease. N Engl J Med 1986; 314: 964-73.
101. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
102. Bekris LM, Millard SP, Galloway NM, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis 2008; 13: 255-66.
103. Yu CE, Seltman H, Peskind ER, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 2007; 89: 655-65.
104. Takei N, Miyashita A, Tsukie T, et al. Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics 2009; 93: 441-8.
105. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 2009; 153B: 409-17.
106. Potkin SG, Guffanti G, Lakatos A, et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 2009; 4: e6501.
107. Roses AD, Lutz MW, Amrine-Madsen H, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 2009.
108. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-8.
109. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273: 942-7.
110. Mosconi L, Brys M, Switalski R, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007; 104: 19067-72.
111. Mosconi L, Mistur R, Switalski R, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009; 72: 513-20.
112. Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid- {beta} burden in normal individuals with a family history of late- onset Alzheimer's. Proc Natl Acad Sci USA 2010; 107: 5949-54.
113. Berti V, Mosconi L, Glodzik L, et al. Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol Aging 2011: Epub ahead of print.
114. Honea RA, Swerdlow RH, Vidoni E, Burns JM. Progressive regional atrophy in normaladults with a maternal history of Alzheimer disease. Neurology 2011; 76: 822-9.
115. Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010; 74: 113-20.
116. Mosconi L, Glodzik L, Mistur R, et al. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 2010; 68: 913-21.
117. Debette S, Wolf PA, Beiser A, et al. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 2009; 73: 2071-8.
118. Stacpoole PW, Kurtz TL, Han Z, Langaee T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 2008; 60: 1478-87.
119. Saitoh S, Momoi MY, Yamagata T, Mori Y, Imai M. Effects of dichloroacetate in three patients with MELAS. Neurology 1998; 50: 531-4.
120. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66: 324-30.
121. Eleff S, Kennaway NG, Buist NR, et al. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci USA 1984; 81: 3529-33.
122. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav 2004; 77: 175-81.
123. Clifton J, 2nd, Leikin JB. Methylene blue. Am J Ther 2003; 10: 289-91.
124. Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008; 22: 703-12.
125. Atamna H, Kumar R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J Alzheimers Dis 2010; 20 Suppl 2: S439-52.
126. Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor (TAI) therapy with rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Azheimer's and Dementia 2008; 4: T167.
127. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59: 1541-50.
128. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003; 61: 1498-502.
129. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-9.
130. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-86.
131. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-70.
132. Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med 2008; 10: 275-90.
133. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001; 49: 561-74.
134. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656-61.
135. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003; 61: 925-30.
136. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006; 67: 1262-4.
137. NINDS-NET PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-71.
138. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF, Jr. Brain metabolism during fasting. J Clin Invest 1967; 46: 1589-95.
139. Kossoff EH, Zupec-Kania BA, Rho JM. Ketogenic diets: an update for child neurologists. J Child Neurol 2009; 24: 979-88.
140. Swerdlow R, Marcus DM, Landman J, Harooni M, Freedman ML. Brain glucose and ketone body metabolism in patients with Alzheimer's disease. Clin Res 1989; 37: 461A.
141. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo- controlled, multicenter trial. Nutr Metab (Lond) 2009; 6: 31.
142. Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 2008; 5: 470-80.
143. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-95.
144. Perry G, Nunomura A, Hirai K, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 2002; 33: 1475-9.
145. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994; 91: 10771-8.
146. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta- analysis. JAMA 2007; 297: 842-57.
147. Parkinsons's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1989; 321: 1364-71.
148. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-22.
149. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23: 942-9.
150. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol 2006; 2006: 31372.
151. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276: 4588-96.
152. Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo- controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010; 25: 1670-4.
153. Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimers Dis 2010; 20 Suppl 2: S633-43.
154. Greco T, Fiskum G. Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis 2010; 20 Suppl 2: S427-37.
155. Schriner SE, Linford NJ, Martin GM, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005; 308: 1909-11.
156. Perez VI, Van Remmen H, Bokov A, Epstein CJ, Vijg J, Richardson A. The overexpression of major antioxidant enzymes does not extend the lifespan of mice. Aging Cell 2009; 8: 73-5.
157. Jang YC, Remmen VH. The mitochondrial theory of aging: insight from transgenic and knockout mouse models. Exp Gerontol 2009; 44: 256-60.
158. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000; 1: 120-9.
159. Crompton M, Virji S, Doyle V, Johnson N, Ward JM. The mitochondrial permeability transition pore. Biochem Soc Symp 1999; 66: 167-79.
160. Lemasters JJ, Theruvath TP, Zhong Z, Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta 2009; 1787: 1395-401.
161. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004; 23: 2861-74.
162. Wang C, Youle RJ. The role of mitochondria in apoptosis*. Annu Rev Genet 2009; 43: 95-118.
163. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
164. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001; 2: 67-71.
165. Czabotar PE, Lessene G. Bcl-2 family proteins as therapeutic targets. Curr Pharm Des 2010; 16: 3132-48.
166. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 437-41.
167. Haroon MF, Fatima A, Scholer S, et al. Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol Dis 2007; 28: 237-50.
168. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-8.
169. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53.
170. Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010; 92: 330-44.
171. Yi H, Maruyama W, Akao Y, et al. N-Propargylamine protects SH- SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 2006; 113: 21-32.
172. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N- methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002; 82: 913-23.
173. Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol 2003; 66: 1635-41.
174. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005; 79: 172-9.
175. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed- start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-78.
176. Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler 2008; 9: 50-8.
177. Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 2010; 21: 389-402.
178. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003; 993: 334-44; discussion 45-9.
179. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 2010; 23: 518-23.
180. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-15.
181. Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science 2010; 327: 1309.
182. Rabinowitz JD, White E. Autophagy and metabolism. Science 2010; 330: 1344-8.
183. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12: 9-14.
184. Banerjee R, Beal MF, Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 2010; 33: 541-9.
185. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21: 3017-23.
186. Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease- locating the primary defect. Neurobiol Dis 2011.
187. Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 2009; 218: 235-46.
188. Chan NC, Salazar AM, Pham AH, et al. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum Mol Genet 2011.
189. Gusdon AM, Chu CT. To Eat or Not to Eat: Neuronal Metabolism, Mitophagy and Parkinson's Disease. Antioxid Redox Signal 2010.
190. Tong Y, Yamaguchi H, Giaime E, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 2010; 107: 9879-84.
191. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 2010; 107: 378-83.
192. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008; 105: 2052-7.
193. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 481-8.
194. Chio A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010; 75: 619-25.
195. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-5.
196. Zemke D, Azhar S, Majid A. The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect 2007; 20: 495-9.
197. Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010; 5: e9979.
198. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 2010; 30: 1166-75.
199. Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel 2010; 13: 31-40.
200. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-95.
201. Kapahi P, Chen D, Rogers AN, et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11: 453-65.
202. Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 2008; 173: 470-82.
203. Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 29: 9090-103.
204. de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 2000; 80: 1323-35.
205. Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002; 80: 616-25.
206. Brown AM, Sheu RK, Mohs R, Haroutunian V, Blass JP. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci 2001; 16: 41-8.
207. Onyango IG, Lu J, Rodova M, Lezi E, Crafter AB, Swerdlow RH. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta 2010; 1802: 228-34.
208. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006; 116: 615-22.
209. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006; 27: 728-35.
210. Houten SM, Auwerx J. PGC-1alpha: turbocharging mitochondria. Cell 2004; 119: 5-7.
211. Feige JN, Auwerx J. Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol 2008; 20: 303-9.
212. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007; 72: 483-8.
213. Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-21.
214. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC- 1{alpha}. J Biol Chem 2005; 280: 16456-60.
215. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-85.
216. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007; 104: 12017-22.
217. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006; 574: 33-9.
218. Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001; 413: 179-83.
219. Wu Z, Huang X, Feng Y, et al. Transducer of regulated CREB- binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. Proc Natl Acad Sci USA 2006; 103: 14379-84.
220. Daitoku H, Yamagata K, Matsuzaki H, Hatta M, Fukamizu A. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 2003; 52: 642-9.
221. Nakae J, Oki M, Cao Y. The FoxO transcription factors and metabolic regulation. FEBS Lett 2008; 582: 54-67.
222. Schieke SM, Phillips D, McCoy JP, Jr., et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006; 281: 27643-52.
223. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007; 450: 736-40.
224. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74.
225. Koo SH, Satoh H, Herzig S, et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 2004; 10: 530-4.
226. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20: 98-105.
227. Canto C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci 2010; 67: 3407-23.
228. Ghosh S, Patel N, Rahn D, et al. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol 2007; 71: 1695-702.
229. Strum JC, Shehee R, Virley D, et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007; 11: 45-51.
230. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005; 54: 1392-9.
231. Bolten CW, Blanner PM, McDonald WG, et al. Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma. Gene Regul Syst Bio 2007; 1: 73-82.
232. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
233. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to- moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246-54.
234. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011; 68: 45-50.
235. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30: 131-46.
236. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008; 8: 249-56.
237. Wenz T, Wang X, Marini M, Moraes CT. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 2010.
238. Navarro A, Gomez C, Lopez-Cepero JM, Boveris A. Beneficial effects of moderate exercise on mice aging: survival, behavior, oxidative stress, and mitochondrial electron transfer. Am J Physiol Regul Integr Comp Physiol 2004; 286: R505-11.
239. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-7.
240. Ingram DK, Young J, Mattison JA. Calorie restriction in nonhuman primates: assessing effects on brain and behavioral aging. Neuroscience 2007; 145: 1359-64.
241. Spindler SR. Biological effects of calorie restriction: From soup to nuts. Ageing Res Rev 2009.
242. Varady KA, Hellerstein MK. Alternate-day fasting and chronic disease prevention: a review of human and animal trials. Am J Clin Nutr 2007; 86: 7-13.
243. Weindruch R, Sohal RS. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med 1997; 337: 986-94.
244. Greer EL, Brunet A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell 2009; 8: 113-27.
245. Boveris A, Navarro A. Systemic and mitochondrial adaptive responses to moderate exercise in rodents. Free Radic Biol Med 2008; 44: 224-9.
246. Fernstrom M, Tonkonogi M, Sahlin K. Effects of acute and chronic endurance exercise on mitochondrial uncoupling in human skeletal muscle. J Physiol 2004; 554: 755-63.
247. Holloszy JO. Adaptation of skeletal muscle to endurance exercise. Med Sci Sports 1975; 7: 155-64.
248. Hood DA. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle. Appl Physiol Nutr Metab 2009; 34: 465-72.
249. Hoppeler H, Fluck M. Plasticity of skeletal muscle mitochondria: structure and function. Med Sci Sports Exerc 2003; 35: 95-104.
250. Civitarese AE, Smith SR, Ravussin E. Diet, energy metabolism and mitochondrial biogenesis. Curr Opin Clin Nutr Metab Care 2007; 10: 679-87.
251. Hepple RT. Why eating less keeps mitochondria working in aged skeletal muscle. Exerc Sport Sci Rev 2009; 37: 23-8.
252. Lambert AJ, Wang B, Yardley J, Edwards J, Merry BJ. The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumption. Exp Gerontol 2004; 39: 289-95.
253. Cassano P, Sciancalepore AG, Lezza AM, Leeuwenburgh C, Cantatore P, Gadaleta MN. Tissue-specific effect of age and caloric restriction diet on mitochondrial DNA content. Rejuvenation Res 2006; 9: 211-4.
254. Nisoli E, Tonello C, Cardile A, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005; 310: 314-7.
255. Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF, Jr. Liver and kidney metabolism during prolonged starvation. J Clin Invest 1969; 48: 574-83.
256. van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 2005; 25: 8680-5.
257. Kempermann G, van Praag H, Gage FH. Activity-dependent regulation of neuronal plasticity and self repair. Prog Brain Res 2000; 127: 35-48.
258. Witte AV, Fobker M, Gellner R, Knecht S, Floel A. Caloric restriction improves memory in elderly humans. Proc Natl Acad Sci USA 2009; 106: 1255-60.
259. Lu J, E L, Wang W, et al. Alternate day fasting impacts the brain insulin-signaling pathway of young adult male C57BL/6 mice. J Neurochem 2011: Epub ahead of print.
260. Sauve AA. Pharmaceutical strategies for activating sirtuins. Curr Pharm Des 2009; 15: 45-56.
261. Fontana L, Partridge L, Longo VD. Extending healthy life span- from yeast to humans. Science 2010; 328: 321-6.
262. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-60.
263. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-63.
264. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-35.
265. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
266. Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 2010; 1804: 1626-34.
267. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006; 96: 305-13.
268. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7: 1020-35.
269. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008; 3: e2264.
270. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
271. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008; 56: 4855-73.
272. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010; 31: 194-223.
273. Blass JP, Gibson GE. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. J Alzheimers Dis 2006; 9: 207-18.
274. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 1997; 15: 212-5.
275. Taylor RW, Wardell TM, Smith PM, et al. An antigenomic strategy for treating heteroplasmic mtDNA disorders. Adv Drug Deliv Rev 2001; 49: 121-5.
276. Kang D, Kim SH, Hamasaki N. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion 2007; 7: 39-44.
277. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611-38.
278. Parisi MA, Clayton DA. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science 1991; 252: 965-9.
279. Ekstrand MI, Falkenberg M, Rantanen A, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet 2004; 13: 935-44.
280. Hayashi Y, Yoshida M, Yamato M, et al. Reverse of age-dependent memory impairment and mitochondrial DNA damage in microglia by an overexpression of human mitochondrial transcription factor a in mice. J Neurosci 2008; 28: 8624-34.
281. Iyer S, Thomas RR, Portell FR, Dunham LD, Quigley CK, Bennett JP, Jr. Recombinant mitochondrial transcription factor A with N- terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression. Mitochondrion 2009; 9: 196-203.
282. Keeney PM, Quigley CK, Dunham LD, et al. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 2009; 20: 897-907.
283. Tanaka M, Borgeld HJ, Zhang J, et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 2002; 9: 534-41.
284. Alexeyev MF, Venediktova N, Pastukh V, Shokolenko I, Bonilla G, Wilson GL. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Gene Ther 2008; 15: 516-23.
285. Bacman SR, Williams SL, Garcia S, Moraes CT. Organ-specific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 2010; 17: 713-20.
286. Khan SM, Bennett JP, Jr. Development of mitochondrial gene replacement therapy. J Bioenerg Biomembr 2004; 36: 387-93.
287. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 2007; 6: 280-93.
288. Mattson MP. Dietary factors, hormesis and health. Ageing Res Rev 2008; 7: 43-8.
289. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1155-63.
290. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 1994; 91: 10625-9.
291. Pellerin L, Magistretti PJ. Food for thought: challenging the dogmas. J Cereb Blood Flow Metab 2003; 23: 1282-6.
292. Halassa MM, Haydon PG. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol 2010; 72: 335-55.
293. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009; 32: 421-31.
294. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006; 209: 2304-11.
295. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life 2001; 52: 3-6.
296. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15: 247-54.
297. Gomez-Cabrera MC, Domenech E, Romagnoli M, et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am J Clin Nutr 2008; 87: 142-9.
298. McGinley C, Shafat A, Donnelly AE. Does Antioxidant Vitamin Supplementation Protect against Muscle Damage? Sports Med 2009; 39: 1011-32.
299. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009; 106: 8665-70.
300. Katzoff A, Ben-Gedalya T, Susswein AJ. Nitric oxide is necessary for multiple memory processes after learning that a food is inedible in aplysia. J Neurosci 2002; 22: 9581-94.
301. Levin ED, Brady TC, Hochrein EC, et al. Molecular manipulations of extracellular superoxide dismutase: functional importance for learning. Behav Genet 1998; 28: 381-90.
302. Lamb HM, Hardwick M. Noncanonical functions of BCL-2 proteins in the nervous system. Adv Exp Med Biol 2010; 687: 115-29.
303. Danial NN, Gimenez-Cassina A, Tondera D. Homeostatic functions of BCL-2 proteins beyond apoptosis. Adv Exp Med Biol 2010; 687: 1-32.
304. Autret A, Martin SJ. Bcl-2 family proteins and mitochondrial fission/fusion dynamics. Cell Mol Life Sci 2010; 67: 1599-606.
305. Bergamini E, Cavallini G, Donati A, Gori Z. The anti-ageing effects of caloric restriction may involve stimulation of macroautophagy and lysosomal degradation, and can be intensified pharmacologically. Biomed Pharmacother 2003; 57: 203-8.
306. Kume S, Uzu T, Horiike K, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010; 120: 1043-55.
307. Barrientos A, Casademont J, Cardellach F, Estivill X, Urbano- Marquez A, Nunes V. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res 1997; 52: 284-9.
308. Barrientos A, Casademont J, Cardellach F, et al. Qualitative and quantitative changes in skeletal muscle mtDNA and expression of mitochondrial-encoded genes in the human aging process. Biochem Mol Med 1997; 62: 165-71.
309. Swerdlow RH, Khan SM. A mitochondrial cascade hypothesis for sporadic Alzheimer's disease. Med Hypotheses 2004; 63: 8-20.
310. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11: 437-44.
311. Li W, Zhang B, Tang J, et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 2007; 27: 2606-16.
312. Suzuki K, Koike T. Mammalian Sir2-related protein (SIRT) 2- mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience 2007; 147: 599-612.
313. Arduino DM, Esteves AR, Oliveira CR, Cardoso SM. Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinson's Disease. CNS Neurol Disord Drug Targets 2009.
314. Esteves AR, Arduino DM, Swerdlow RH, Oliveira CR, Cardoso SM. Microtubule depolymerization potentiates alpha-synuclein oligomerization. Front Aging Neurosci 2010; 1: 5.
315. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317: 516-9.
316. Green KN, Steffan JS, Martinez-Coria H, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008; 28: 11500-10.